Essen Biotech

Focus: Essen Biotech is a German-headquartered biotechnology company specializing in advanced cell and gene therapies, focusing on CAR-T, TILs, and CRISPR-Cas9 gene editing platforms. The company operates in the high-innovation, capital-intensive immuno-oncology and genetic medicine space.

Gene Therapy Cell Therapy

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Essen Biotech

AI assessmentNot Hiring

No open roles listed right now. Follow Essen Biotech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

17 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Tumor Infiltrating Lymphocytes

Stomach Cancer

Phase 1/2

Clinical Trials (1)

NCT06532799TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

Phase 1/2

Help build intelligence for Essen Biotech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Exposure to cutting-edge modalities (CAR-T, TILs, CRISPR) with significant unmet medical need and commercial potential
Early-stage biotech environment offers high responsibility and direct impact on program strategy and clinical development
German biotech hub location provides access to strong academic and research infrastructure

Watch Out For

Zero active job openings and minimal available hiring information suggests company is not in expansion mode or is in stealth/restructuring phase
No disclosed revenue, funding, employee count, or pipeline data creates significant uncertainty about company viability, burn rate, and cash runway
No clinical trials in development (0 Phase 1/2/3 programs) indicates company may be in preclinical stage or facing development challenges

Generated by Claude from Essen Biotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

EBNK-001 + IL-15 + Pembrolizumab

Cancer

Phase 1/2

Clinical Trials (1)

NCT07410676EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

Phase 1/2

Tumor Infiltrating Lymphocytes

Colorectal Cancer

Phase 1/2

Clinical Trials (1)

NCT06530303Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer

Phase 1/2

Tumor Infiltrating Lymphocytes

Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT06532812TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

Phase 1/2

EB-SELECT Single-Target CAR-NK Cells

Cancer

Phase 1/2

Clinical Trials (1)

NCT07410494Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Phase 1/2

CD19/CD22-CAR T cells

Acute Lymphoblastic Leukemia, Adult B-Cell

Phase 1/2

Clinical Trials (1)

NCT06213636Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

Phase 1/2

Mesothelin and Claudin 18.2 CAR-T cells

Pancreatic Cancer

Phase 1/2

Clinical Trials (1)

NCT07066995Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer

Phase 1/2

BCMA/GPRC5D CAR-T cells

Multiple Myeloma

Phase 1/2

Clinical Trials (1)

NCT07032129Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma

Phase 1/2

Tumor Infiltrating Lymphocytes

Brain Tumor

Phase 1/2

Clinical Trials (1)

NCT06640582TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

Phase 1/2

CD5/CD7 CAR-T

T Cell Lymphoma

Phase 1/2

Clinical Trials (1)

NCT06420076Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells

Phase 1/2

BCMA/CD19 CAR-T cells

Autoimmune Diseases

Phase 1/2

Clinical Trials (1)

NCT06428188Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases

Phase 1/2

CD19- BCMA CAR-T cells

Systemic Lupus Erythematosus

Phase 1/2

Clinical Trials (1)

NCT06350110Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)